MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$300,000K
Proceeds from
refinancing under loan and...
$23,338K
Proceeds from maturities
of marketable...
$506,162K
Proceeds from exercise of
stock options and...
$6,981K
Proceeds from short swing
settlement
$500K
Net cash provided by
financing activities
$308,897K
Net cash provided by
(used in) investing...
$194,286K
Canceled cashflow
$21,922K
Canceled cashflow
$311,876K
Net increase in cash
and cash...
$262,079K
Canceled cashflow
$241,104K
Payment of issuance
costs and...
$18,405K
Payment of deferred
issuance costs related to...
$3,517K
Stock-based compensation
$37,926K
Accrued and other
liabilities
$14,442K
Accounts payable
$13,910K
Accretion of loan exit fee
and amortization of...
$1,857K
Reduction in the carrying
amount of operating...
$1,449K
Payment of vt-109
license fee
$800K
Depreciation and
amortization
$468K
Other assets
-$51K
Purchase of marketable
securities
$310,446K
Payment of vt-109
license fee
$800K
Purchase of property and
equipment
$630K
Net cash used in
operating activities
-$241,104K
Canceled cashflow
$70,903K
Net loss
-$299,615K
Accretion of discount and
amortization of premium on...
-$6,981K
Prepaid expense and
other current assets
$3,928K
Operating lease
liabilities
-$1,483K
Back
Back
Cash Flow
source: myfinsight.com
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)